Clinical Trial Update: Study on the Treatment of Differentiated Thyroid Carcinoma with Anlotinib [Phase 2]

View source ↗

Summary

Phase 2 clinical trial update investigating Anlotinib for differentiated thyroid carcinoma is currently active but not recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Differentiated Thyroid Carcinoma

Drugs mentioned

• Anlotinib (anlotinib)

Snippet

Sponsor: Yansong Lin | Conditions: DTC - Differentiated Thyroid Cancer | Phase 2 | Status: ACTIVE_NOT_RECRUITING